|
|
 |
|
Viewing report
|
|
|
|
Premium Company Profile - Amylin Pharmaceuticals
Datamonitor, Oct 2007, Pages: 59
Introduction
Amylins main focus is to develop and commercialize products for the treatment of diabetes and obesity. The companys marketed brands consist of Byetta, which is used for the treatment of patients with type 2 diabetes, and Symlin, indicated for use in adults with type 2 or type 1 diabetes.
Scope
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Amylin derives its revenues from marketing of pharmaceutical products and from collaborative agreements to develop and commercialize its products in other countries with other pharmaceutical companies. The companys major contributor to revenue growth during 2002-2006 was product sales of Byetta and Symlin. Amylins biggest contributor to sales growth out to 2010 will remain to be from Byetta sales. Revenues from Byetta during the period 2006-2010 are forecasted to grow at a CAGR of 40% from $430 million to $1,652 million. Apart from in-house research and development, the company aims to leverage its development resources through collaborations with other pharmaceutical and biotechnology companies such as Eli Lilly and Alkermes.
Reasons to Purchase
- Access all the important information and analysis on the company in a single report
- Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to companys adjusted five year financial data along with key ratios and market capitalization
Customers who bought this item also bought
Amylin Pharmaceuticals, Inc. - SWOT Analysis
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
Analysis of Amylin Pharmaceuticals
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals - SWOT Framework Analysis
Amylin Pharmaceuticals Inc-Therapeutic Competitors
Byetta FDA Update Call - Eli Lilly & Co.,Amylin Pharmaceuticals, Inc., - Earnings Transcript
Byetta FDA Update Call - Eli Lilly & Co.,Amylin Pharmaceuticals, Inc., - Earnings Transcript
Byetta FDA Update Call - Eli Lilly & Co.,Amylin Pharmaceuticals, Inc., - Earnings Transcript
Q3 2009 Earnings Call - Amylin Pharmaceuticals, Inc., - Earnings Transcript
Q3 2009 Earnings Call - Amylin Pharmaceuticals, Inc., - Call Street Report
|
|
|
|
